tiprankstipranks
Advertisement
Advertisement

PCREMEP Stock Latest News

Remepy Secures $36 Million Series A to Advance Hybrid Drug Platform and Parkinson’s Phase III Trial
Private CompaniesRemepy Secures $36 Million Series A to Advance Hybrid Drug Platform and Parkinson’s Phase III Trial
11h ago
REMEP
Remepy’s TGCT & Me App Gains UX Design Award Nomination
PremiumPrivate Companies
Remepy’s TGCT & Me App Gains UX Design Award Nomination
6d ago
REMEP
Remepy Advances Hybridopa Parkinson’s Program Toward Phase 3 Design
PremiumPrivate Companies
Remepy Advances Hybridopa Parkinson’s Program Toward Phase 3 Design
8d ago
REMEP
Digital Support Initiative Targets Rare Sarcoma Patients
PremiumPrivate Companies
Digital Support Initiative Targets Rare Sarcoma Patients
13d ago
REMEP
Remepy – Weekly Recap
PremiumPrivate Companies
Remepy – Weekly Recap
1M ago
REMEP
Remepy’s TGCT & Me App Recognized in UX Design Awards 2026
PremiumPrivate CompaniesRemepy’s TGCT & Me App Recognized in UX Design Awards 2026
1M ago
REMEP
Remepy Advances Hybridopa With New Parkinson’s Data and Hybrid Drug Visibility
Premium
Private Companies
Remepy Advances Hybridopa With New Parkinson’s Data and Hybrid Drug Visibility
1M ago
REMEP
Remepy Highlights New Parkinson’s Data as It Prepares Hybridopa for Phase 3
Premium
Private Companies
Remepy Highlights New Parkinson’s Data as It Prepares Hybridopa for Phase 3
1M ago
REMEP
Remepy Advances Hybridopa Toward Phase III With New Mechanistic Data in Parkinson’s Disease
PremiumPrivate Companies
Remepy Advances Hybridopa Toward Phase III With New Mechanistic Data in Parkinson’s Disease
1M ago
REMEP
Remepy Showcases Hybrid Drug Concept at Tech Tour Growth Health Event
PremiumPrivate Companies
Remepy Showcases Hybrid Drug Concept at Tech Tour Growth Health Event
1M ago
REMEP
Remepy Advances Hybridopa Toward Phase 3 as TGCT App Gains Clinical Spotlight
PremiumPrivate Companies
Remepy Advances Hybridopa Toward Phase 3 as TGCT App Gains Clinical Spotlight
2M ago
REMEP
Remepy Highlights Phase IIa Hybridopa Data and Targets Phase 3 Parkinson’s Trial in Q3
PremiumPrivate Companies
Remepy Highlights Phase IIa Hybridopa Data and Targets Phase 3 Parkinson’s Trial in Q3
2M ago
REMEP
Remepy Advances Phase 3 Parkinson’s Plans and Expands TGCT Digital Footprint
PremiumPrivate CompaniesRemepy Advances Phase 3 Parkinson’s Plans and Expands TGCT Digital Footprint
2M ago
REMEP
Phase 3 Parkinson’s Trial Engagement Signals Advancing Pipeline at Remepy
Premium
Private Companies
Phase 3 Parkinson’s Trial Engagement Signals Advancing Pipeline at Remepy
2M ago
REMEP
Remepy Highlights Engagement Around Phase 3 Parkinson’s Trial at WPC2026
Premium
Private Companies
Remepy Highlights Engagement Around Phase 3 Parkinson’s Trial at WPC2026
2M ago
REMEP
Remepy Showcases TGCT & Me Patient Support App at Major Oncology Conference
PremiumPrivate Companies
Remepy Showcases TGCT & Me Patient Support App at Major Oncology Conference
2M ago
REMEP
Remepy’s TGCT & Me App Highlighted at Major Oncology Conference
PremiumPrivate Companies
Remepy’s TGCT & Me App Highlighted at Major Oncology Conference
2M ago
REMEP
Remepy – Weekly Recap
PremiumPrivate Companies
Remepy – Weekly Recap
2M ago
REMEP
Remepy Highlights U.S. Launch of TGCT & Me Rare Disease Support App
PremiumPrivate Companies
Remepy Highlights U.S. Launch of TGCT & Me Rare Disease Support App
3M ago
REMEP
Remepy Highlights U.S. Launch of TGCT & Me Rare-Disease Support App
PremiumPrivate CompaniesRemepy Highlights U.S. Launch of TGCT & Me Rare-Disease Support App
3M ago
REMEP
Remepy Advances Hybridopa After Strong Phase IIa Parkinson’s Data and Eyes 2026 Phase III Launch
Premium
Private Companies
Remepy Advances Hybridopa After Strong Phase IIa Parkinson’s Data and Eyes 2026 Phase III Launch
3M ago
REMEP
Remepy Highlights Positive Phase IIa Results for Hybridopa in Parkinson’s Disease
Premium
Private Companies
Remepy Highlights Positive Phase IIa Results for Hybridopa in Parkinson’s Disease
3M ago
REMEP

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >